Semi-synthetic VNAR Libraries for High-Affinity Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional antibody molecules have limitations such as restricted antigen activity, poor tissue penetration, unwanted effector function, high manufacturing costs, and product instability, which are not adequately addressed by existing VNAR libraries that rely on CDR3 randomization of a single VNAR clone.
Innovation Solution
Development of semi-synthetic VNAR libraries from nurse shark sequences, incorporating backbone mutations and partial randomization of CDR3 regions to increase diversity, allowing for the identification of high-affinity binding moieties to specific cellular targets, including Type 2 VNAR libraries with additional framework mutations and Type 1 VNAR libraries biased for long CDR3 regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibody molecules are used, then high specificity and affinity for target antigen can be achieved, but tissue penetration is poor and manufacturing cost is high
Solution Approach 1:
The patent extracts and utilizes only the variable region (VNAR) from the shark heavy-chain antibody, discarding the constant regions and light chains. This extraction creates a minimized binding domain that retains antigen specificity while reducing molecular size from the full antibody scale to approximately 15 kDa, enabling better tissue penetration while maintaining binding reliability
Solution Approach 2:
The patent segments the antibody molecule into its functional components, isolating the variable region as a separate, independent binding unit. This segmentation allows the VNAR to function as a standalone therapeutic agent without requiring the full antibody structure, thereby reducing size while preserving the essential binding function
2Reliability
If VNAR libraries with CDR3 randomization of a single clone are used, then binding specificity can be improved, but sequence diversity is insufficient
Solution Approach 1:
The patent merges multiple VNAR clones from different shark species into a single library construct, combining their variable regions to create a diverse pool of binding specificities. This merging approach accumulates sequence diversity from multiple natural sources while maintaining the simplified VNAR structure, thereby achieving both specificity and versatility
Solution Approach 2:
The patent creates a universal VNAR library framework that can bind to multiple different antigens by incorporating sequences from various shark species. This multi-functional library design allows a single platform to generate binders against diverse targets, enhancing adaptability while maintaining the core VNAR binding mechanism
3Reliability
If VNAR libraries with CDR3 randomization of a single clone are used, then binding affinity can be optimized, but the library complexity is too low
Solution Approach 1:
The patent combines multiple pre-characterized VNAR clones with known binding properties into a unified library system. By merging sequences from different shark species and validating their individual binding capabilities beforehand, the library achieves high complexity and broad affinity range without requiring de novo randomization of every position, thereby managing complexity efficiently while maintaining high binding affinity potential
Data Source
AI summary
The present invention relates to VNAR single chain antibodies and more particularly, to semi-synthetic VNAR libraries derived from nurse shark which may be used to identify individual clones, nucleic acid molecules and polypeptides which encode binding moieties that specifically bind to a cellular target of interest, thereby altering (e.g., antagonizing) target activity in a cell or mimicking the activity of a native molecule. The present invention thus also relates to compounds and compositions comprising a target specific VNAR binding moiety, methods for preparing them, and diagnostic and therapeutic methods of use relating to regulation, e.g., agonism or antagonism of the selected cellular target or target pathway e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to alter, e.g., agonize or augment, antagonize, reduce or eliminate the specific cellular target activity.